Updates

September 04, 2026 National Stock Exchange of India Limited Exchange Plaza, Plot No. C/1, G Block, Bandra - Kurla Complex, Bandra (East), Mumbai 400 051 Trading Symbol: FERMENTA Dear Sir, Sub: Resubmission of the following outcome filed on August 11, 2026, in machine readable format, in response to the e-mail received dated September 03, 2026. Outcome of Board Meeting and Unaudited Financial Results – pursuant to Regulations 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (‘Listing Regulations’). We write to inform you that the Board of Directors of the Company, at its meeting held on August 11, 2026, has, inter alia, approved the Unaudited Financial Results (Standalone and Consolidated) for the quarter ended June 30, 2026. We are also enclosing herewith the Limited Review Reports on the aforesaid results (Standalone and Consolidated) issued by M/s. SRBC & Co. LLP, Chartered Accountants, Statutory Auditors of the Company with an unmodified opinion on the above-mentioned financial results dated August 11, 2026. Kindly take the above on record. The Board meeting commenced at 11:00 a.m. (IST) and concluded at 01:10 p.m. (IST). Thanking you, Yours faithfully, For Fermenta Biotech Limited Varadvinayak Khambete Company Secretary & Head - Legal Membership No. A33861 Encl: As above SRB C&C OL LP 12tFhl oTohrRe,u by 29S enaBpaaptMaiat r g Dad(aWre st) ChartAecrceodu ntants Mumb·a4 i0002 8I,n dia Tel+ 921:2 6 81890 00 IndepeAnuddeinttRo erv'iRsee wp oorntt h Qeu arteUrnlayu dSittaendd aFlionnaenR ceisauollft t hse Company PtuoRr esguual3na3ott ft i hoSenE (BLIi sOtbilnigga antDdii osncsl Roesquurier eRmeegnutlsa)t ions, 201a5sa, m ended ReviReewp otrot ThBeo aorfDd i rectors FermeBnitoatL eicmhi ted 1.Weh avree vietwhaeecd c ompasntyaitneogmfu e nnatu dsittaendd failnoanrneec siuoalflFt esr menta BiotLeicmhi( tte"hdCe o mpafnotyrhq" eu) arter e3n02d,0e 2(d6t "hJSeut naet eamtetnathc"eh)re edw ith, beisnugb mibtytt heCedo mpapnuyr sutaotn htre e quiroefmR eengtusl3 a3to ifto hnSe E B(IL isting ObligaantDdii osncslR oesquurier eRmeegnutlsa2)t0 i1ao5san, ms e,n de"dL i(stRtheiegn ugl ations"). 2.ThCeo mpaMnayn'asg eimrsee nstp ofnostrih bpelr ee paroaftt hSieto ant eimnaec ncto rwdiatnthch ee recogannimdte iaosnu rpermiennctli adpioldwe insIn n dAicacno uSnttainn3dg4a (,rI dAn Sd3 4")I nterim FinaRnecpioarlpt riensgc"ur nidbSeeerdc t1i3oo3nf t hCeo mpaAnci2te0,s1 a3sa mendreedaw,di th relervualnietss s utehde reuanndde roa tchceoru pnrtiinncggi epnleerasac lcleypi tnIe ndda inadi n compliwaintRchee g ul3a3to ifto hnLe i stRienggul aTthiSeot nast.e hm.ebaneste anp probvyte hde CompaBnoya'orsfDd i recOturorer ssp.o nistsioe b xiplraiec tsoysn clounts hiSeot na tebmaesnoetnod u r review. 3.Wec onduocutrree dv ioeftw h Set ateimnae cncto rdwainttchhSe et andoanRr edv iEenwg agements (SR2E4)1" 0R,e voifIe nwt erimI nFfionramnPacetiriafolobn ryt m heIedn depeAnuddeiontftto h Eren tity" issbuyte hdIe n stoifCt huatret Aecrceodu notfIa nndtisas .t aTnhrdieasqr udti hrwaeetps l aannpd e rform three vtioeo wb tmaoidne raastseu raastn owc hee tthheSert ateimfser noetfme a temriisaslt atAement. revioefiw n tefriinma inncfioarlmc aotnisooifmns a tksii nngq uiprriiemsoa,frp ielrysr oenssp onfsoirble finaanncdai caclo umnattitnaegnr das p,p laynianlgy atnidoc tahlre erv iperwo cedAu rreesvi.is ew substalnetsiisnsa cloltpyhe a anna udciotn duicnta ecdc ordwaintSchte a ndoanrA dusd iatnindg conseqduoeennsote tln ya ubslt eoo btaasisnu rtahnwacetwe o ubledc oamwea orafe ls li gnimfaitctaenrts that bmeii dgehntti ianfn ai uedAdic tc.o rdwiedn ong oletyx ,p raenas usdo ipti nion. 4.Basoenod u rre vcioenwd uacsat beod,vn eothhiacnsog m teoo uart tentthciaaotun us set sob elitehvaet thaec compaSntyaitnegpm reenptai,rna e cdc orwdiatnthchr eee cogannimdte iaosnu repmreinntc iples ladiodw innt haef oreIsnadiAidca cno uSnttainndg(a 'rIAdnSsds' )p eciufnidSeeedrc t1i3oo3nf t he CompaAnci2te0,s1 a3sa mendreeda,d rweiltehrv ualnets tihsesrueeuadnn dodet rha ecrc ounting principleasc cgeeipnnIte nerddhai alansl,o dy ti scltohisene fdo rmraetqiutoiobnr e ed di sclinot seerdm s oft hLei sRteignugl aitnicolntushdm,eia nngni ewnrh iicithts ob ed iscloorts heiacdtto, n taanimyna st erial misstatement. FosrR B& c CoL L P ChartAecrceodu ntants ICFAiIrr me gistnruamtb3ie2or4n:9 82E/E300003 pePro onTaomd arwal Partner MemberNsoh1.i3:p6 454 UDI.u;N :1 3 G f> 45'f H� �W L. 4 ;:,0 \ t 7J Mumbai Augu1s12t,0 26 SRB C C&OL LPaL, i mitedP aLritanbewirilstihhti yp L LP AIAdBe-n4t3i1t8y No. RegOdf.f i2c2Ce,a: m aSct reBelto',cB k3' r,Fd l oKoorl,k at0a1-67 00 FermeBnitoatl eicmhi ted CNlL: 9 9999MH1951PLC008485 RegOdf.f Aic-e1:5T 0h1a,On nee D,IC Lo mplGehxo,d buRnodaeMdra, j iwTahdaa(n,We e 4s0t60)1 0M,a harasIhntdriaa,. Fermenta Tel:+91-22F-a6x7:9+89018-8282,- 67i9n8f0o9@9f9e,rEmmeanitlaW:be ibostwiewtcweh.:.f ceormm,e ntabiotech.com 'I! Liank hs STATEMOEFSN TTA NDALUONNAEU DIFTIENDA NRCEISAULFL OTTRSH QEU ARTEENRD EJDU N3E02 ,0 26 Standalone QuartEenrd ed YeaErn ded Sr. Particulars UnauditedA udited UnauditedA udited Mar3c1h, Mar3c1h, No. Jun3e02 ,0 26 Jun3e02 ,0 25 2026 2026 (No9t)e 1 Income a)R evenfureoo mp era(trieonfnoest4r e) 11,183.931 0,987.631 1,901.874 5,025.27 b)O thienrc ome 489.66 609.88 884.08 2,389.89 2 TotIanlc o(mae+ b) 11,673.591 1,597.511 2,785.954 7,415.16 3 Expenses a)C osotfm atercioanlssu( mreednf oet6re) 4,485.76 3,641.51 3,179.011 6,656.99 b)P urchoafss teosc k-in-trade 130.19 231.73 536.38 1,150.05 c)C hanignie n venotfof riineigsso hoedsdst ,o ck-iannw-dot rrka-dien -progress (1,062.56{)3 84.66) 908.90 (2,470.98) d)E mplobyeenee efxiptes(n rseenf oet1re0 ) 2,005.15 1,832.04 1,897.28 7,413.83 e)F inacnocset s 253.91 276.59 310.50 1,148.44 fD)e precainaadtm ioornt iesxapteinosne 518.61 508.19 554.73 2,093.63 gO)t heexrp enses 3,327.95 3,483.27 3,127.231 3,195.70 Toteaxlp en(sate osg ) 9,659.01 9,588.671 0,514.033 9,187.66 4 Probfeiftot ra(ex2 -3) 2,014.58 2,008.84 2,271.92 8,227.50 5 Exceptiitoeinmnascl o /m( eexpe(nrseenfsoe)t7r e 8 &) 907.14 . 696.62 6 ProaffittEe xrc eptioannabdle fIottrae(exm4 s- 5) 2,014.58 2,915.98 2,271.92 8,924.12 7 Taexx pense a)C urrteanxt 436.09 377.45 400.38 1,460.72 b)D eferred tax charge 79.91 381.25 248.16 1,035.04 Tottaaelxx pe(nas+eb ) 516.00 758.70 648.54 2,495.76 8 Proffoitrth p ee rioda/fytteeaa(rxr6 -7) 1,498.58 2,157.28 1,623.38 6,428.36 9 OthCeorm prehIenncsoimvee (A)iI )t etmhswa tin lolbt er eclatsosP irfooifrLei odts s 32.68 32.68 iiI)n cotmatexh ereon . (8.23) . (8.23) (BIlt etmhswa itb lerl e clatsosP irfooifrLei odts s (iN)ef ta viarl cuhea nignie n vesitnme eqnuitint syt rutmhernootutsgh he r (0.68) (4.37) 6.82 (6.68) iiI)n cotmatexh ereon. 0.17 1.68 . 1.68 Totoatlhc eorm prehlenncsoimvee/ (Loss) (0.15 1) 21.76 6.82 19.45 10 TotCaolm prehIenncsoifmvoteerh pee riod{/8y+e9a)r 1,498.07 2,179.04 1,630.20 6,447.81 11 Paide-quupsi htaycr aep i(tFaavlca el'I! u5 e-/p esrh are) 1,434.03 1,433.53 1,458.45 1,433.5S3 111£DF OIRD ElIIfATlTiCet. 12 Otheeqru (ietxyc lruedvianlgur aetsieornv e) 40,848.0B4 Y 13 Earnpienergq su sihtayor f'I!e e5a c(hn aontn ualised) Earnpienergq su sihtayor f'I!e e5a cbhe feorxec eptiitoenmasl a) 'I!B asic 4-- 5.23 5.26 5.57 20.43 SR BC &C O LLP b} "!Diluted 0� 5.13 5.21 5.56 20.27 MUMBAI Earnpienergq su sihtayor f'I!e e5a cahf teexrc eptiitoenmasl a) 'I!B asic Iil!.:� ' �� � 5.23 7.49 5.57 22.13 b) 'I!D iluted , ..,,,, -r, u• • ,.,,,._ 5.13 7.43 5.56 21.96 Seaec compannoyttieonts gh S et andaflionnarene csiuall..t,.,. s� \ ·�·•"-!;; J_ JI � .(> NOTES: 1.SegmeInntf ormation �i nl akhs Standalone QuarEtnedre d YeaErn ded UnauditedA udited UnauditedA udited Particulars Mar3c1h, Mar3c1h, Jun3e02 ,0 26 Jun3e02 ,0 25 2026 2026 (No9t)e Segmreenvte nue -Budlrku gs/chemicals 11,341.961 1,270.041 1,672.434 4,372.65 -Prop(eRretNfyoe tr4e ) 199.36 188.43 355.22 951.27 -Unallo(cRaetNfeoedtr5 e ) 132.27 139.04 758.30 2,091.24 TotIanlc ome 11,673.591 1,597.511 2,785.954 7,415.16 Segmreenstu [Showing first 8,000 characters — download PDF for full document]